Michael Zilly

No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.

Ralf Winzer, Peter Langmann, Michael Zilly et al. · PubMed · 2003 · 65 citations

Lipid Lowering Therapy with Fluvastatin and Pravastatin in Patients with HIV Infection and Antiretroviral Therapy: Comparison of Efficacy and Interaction with Indinavir

Andreas Benesic, Michael Zilly, Friedrich Kluge et al. · Infection · 2004 · 62 citations

Antiretroviral Therapy, Cardiovascular Disease, Treatment And Prevention +9

High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy

Peter Langmann, Diana Schirmer, Thomas Väth et al. · Journal of Chromatography B Biomedical Sciences and Applications · 2001 · 42 citations

Human Retrovirus, Bioanalysis, Pharmacology +8

High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir in plasma of patients during highly active antiretroviral therapy

Peter Langmann, Hartwig Klinker, Diana Schirmer et al. · Journal of Chromatography B Biomedical Sciences and Applications · 1999 · 40 citations

Antiviral Compound, Medicine, Bioanalysis +12

Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.

Peter Langmann, Steffen Desch, Thomas Väth et al. · PubMed · 2002 · 39 citations